Cargando…
Fasting during Ramadan: efficacy, safety, and patient acceptability of vildagliptin in diabetic patients
Diabetes management during Ramadan fasting is challenging to the physician in terms of minimizing the risk of hypoglycemia. As compared to oral hypoglycemic agents (OHAs) and sulfonylureas (SUs), which carry a higher and significant risk of hypoglycemia, newer antidiabetic agents such as dipeptidyl...
Autor principal: | Aziz, Kamran MA |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4404947/ https://www.ncbi.nlm.nih.gov/pubmed/25931826 http://dx.doi.org/10.2147/DMSO.S54683 |
Ejemplares similares
-
Profile of vildagliptin in type 2 diabetes: efficacy, safety, and patient
acceptability
por: Pan, CY, et al.
Publicado: (2013) -
Experience with Vildagliptin in Type 2 Diabetic Patients Fasting During Ramadan in France: Insights from the VERDI Study
por: Halimi, Serge, et al.
Publicado: (2013) -
The effect of vildagliptin relative to sulphonylureas in Muslim patients with type 2 diabetes fasting during Ramadan: the VIRTUE study
por: Al-Arouj, M, et al.
Publicado: (2013) -
Effect of Vildagliptin Versus Sulfonylurea in Muslim Patients with Type 2 Diabetes Fasting During Ramadan in Egypt: Results from VIRTUE Study
por: Khattab, Mohamed, et al.
Publicado: (2016) -
A double-blind, randomized trial, including frequent patient–physician contacts and Ramadan-focused advice, assessing vildagliptin and gliclazide in patients with type 2 diabetes fasting during Ramadan: the STEADFAST study
por: Hassanein, Mohamed, et al.
Publicado: (2014)